Ladiratuzumab (hLIV22) is a humanized monoclonal antibody specifically targeting the zinc transporter LIV-1/ZIP6. This antibody is chemically linked to monomethyl auristatin E (MMAE) through a cleavable dipeptide linker, forming the antibody-drug conjugate (ADC) known as Ladiratuzumab vedotin. Designed for precision in oncological therapies, Ladiratuzumab vedotin binds selectively to the LIV-1 protein, which is frequently overexpressed on the surface of various tumor cells. Upon binding, the conjugate is internalized via receptor-mediated endocytosis, facilitating the intracellular release of MMAE. This potent cytotoxic agent acts by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis of the tumor cells. Additionally, Ladiratuzumab vedotin exhibits a bystander effect, where the cytotoxic agent can diffuse and eliminate neighboring tumor cells, enhancing its therapeutic efficacy. This ADC is particularly relevant in research focused on solid tumors, including metastatic triple-negative breast cancer (mTNBC), where conventional treatments often fall short.
Ladiratuzumab (hLIV22) is a humanized monoclonal antibody specifically targeting the zinc transporter LIV-1/ZIP6. This antibody is chemically linked to monomethyl auristatin E (MMAE) through a cleavable dipeptide linker, forming the antibody-drug conjugate (ADC) known as Ladiratuzumab vedotin. Designed for precision in oncological therapies, Ladiratuzumab vedotin binds selectively to the LIV-1 protein, which is frequently overexpressed on the surface of various tumor cells. Upon binding, the conjugate is internalized via receptor-mediated endocytosis, facilitating the intracellular release of MMAE. This potent cytotoxic agent acts by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis of the tumor cells. Additionally, Ladiratuzumab vedotin exhibits a bystander effect, where the cytotoxic agent can diffuse and eliminate neighboring tumor cells, enhancing its therapeutic efficacy. This ADC is particularly relevant in research focused on solid tumors, including metastatic triple-negative breast cancer (mTNBC), where conventional treatments often fall short.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
